Pacific Shuanglin Bio-pharmacy (000403.SZ): Registration clinical trials of human thrombin drug accepted
China Paclin Biology (000403.SZ) announced that its wholly-owned subsidiary Guangdong Shuanglin Biopharmaceutical Co., Ltd. ("Guangdong Shuanglin") has received the "Acceptance Notification" for the clinical trial registration of human thrombin approved and issued by the National Medical Products Administration. The indications for human thrombin application are: external use only, used for oozing and minor bleeding in capillaries and small veins, and as an adjunct hemostatic when bleeding control through standard surgical techniques is ineffective or impractical. This product can be used in combination with absorbable gelatin sponge and other materials.
Pacific Shuanglin Bio-pharmacy (000403.SZ) announced that its wholly-owned subsidiary Guangdong Shuanglin Bio-pharmaceutical Co., Ltd. (referred to as "Guangdong Shuanglin") has received the drug registration clinical trial "Acceptance Notice" issued by the National Medical Products Administration for human thrombin. The indications for human thrombin application are: only for external use, for capillary and small vein oozing and minor bleeding, and as an adjunctive hemostatic agent when bleeding cannot be controlled effectively or is impractical through standard surgical techniques. This product can be used in combination with absorbable gelatin sponge and other materials.
Related Articles
DA YU FIN (01073) subsidiary sells notes with a face value of $1 million for approximately 5.9 million Hong Kong dollars at a discount.
Shanghai Fosun Pharmaceutical(02196): The drug registration application for cyclophosphamide injection has been accepted.
Tsaker NE (01986) cancelled 838,000 repurchased shares.
DA YU FIN (01073) subsidiary sells notes with a face value of $1 million for approximately 5.9 million Hong Kong dollars at a discount.
Shanghai Fosun Pharmaceutical(02196): The drug registration application for cyclophosphamide injection has been accepted.
Tsaker NE (01986) cancelled 838,000 repurchased shares.
